<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-132923" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Etesevimab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Balasundaram</surname>
            <given-names>Palanikumar</given-names>
          </name>
          <aff>University of Illinois College Medicine of Rockford, &#x00026; Javon Bea Hospital, Mercy Health System, IL</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Morgan-Joseph</surname>
            <given-names>Toshiba</given-names>
          </name>
          <aff>Montefiore Medical Center/ Albert Einstein Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Palanikumar Balasundaram declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Toshiba Morgan-Joseph declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-132923.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">As of January 24, 2022, the United States Food and Drug Associated (FDA) fact sheet for the drug etesevimab states that "due to the high frequency of the Omicron variant, bamlanivimab and etesevimab, administered together, are not currently authorized for use in any U.S. region because of markedly reduced activity against the Omicron variant. These drugs may not be administered for treatment or post-exposure prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency." This&#x000a0;topic is for historical purposes only to review this therapy's indications, mechanism, and administration when it was first developed.&#x000a0;</p>
        <p>Several neutralizing monoclonal antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) are under clinical trials. Neutralizing monoclonal antibodies are recombinant proteins derived from the B cells of convalescent patients or humanized mice. Before SARS-CoV-2, monoclonal antibodies were developed to treat several viral infections, such as Ebola, Rabies, and Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).<xref ref-type="bibr" rid="article-132923.r1">[1]</xref><xref ref-type="bibr" rid="article-132923.r2">[2]</xref><xref ref-type="bibr" rid="article-132923.r3">[3]</xref><xref ref-type="bibr" rid="article-132923.r4">[4]</xref>&#x000a0;Etesevimab, bamlanivimab, casirivimab, and imdevimab are some monoclonal antibodies specifically targeting SARS-CoV-2 undergoing current clinical studies. Etesevimab is a human recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor-binding domain. Etesevimab is commonly labeled as LY-CoV016 or as JS016.</p>
        <p>Neutralizing monoclonal antibodies against SARS-CoV2 are available as&#x000a0;2 combination products.</p>
        <list list-type="order">
          <list-item>
            <p>Etesevimab and bamlanivimab&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Imdevimab and casirivimab.<xref ref-type="bibr" rid="article-132923.r5">[5]</xref><xref ref-type="bibr" rid="article-132923.r6">[6]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The FDA (Food and Drug Administration) has approved both combination products through EUA (Emergency Use Authorizations), which can be used for mild to moderate SARS-CoV-2 in non-hospitalized patients at high risk for progressing to severe disease. FDA has revoked the use of bamlanivimab alone for SARS-COV-2 because of many resistant SARS-CoV-2 strains.&#x000a0;The combination product (etesevimab and bamlanivimab) can be used in adults and pediatrics if they are at least 12 years of age and weigh 40 kg or more with mild to moderate SARS CoV-2.&#x000a0;The patients are considered at high risk of progressing to severe COVID-19 or hospitalization if they satisfy&#x000a0;1 of the criteria below:</p>
        <list list-type="order">
          <list-item>
            <p>Body mass index 35 and above</p>
          </list-item>
          <list-item>
            <p>Age above 65 years</p>
          </list-item>
          <list-item>
            <p>Chronic Renal disease</p>
          </list-item>
          <list-item>
            <p>Pregnancy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diabetes Mellitus</p>
          </list-item>
          <list-item>
            <p>Immunosuppressive disease or immunosuppressive treatment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cardiovascular disease, including congenital heart disease</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Chronic respiratory disorders, eg, COPD (chronic obstructive pulmonary disease), Moderate to severe asthma, ILD (interstitial lung disease), and pulmonary hypertension</p>
          </list-item>
          <list-item>
            <p>Sickle cell disease</p>
          </list-item>
          <list-item>
            <p>Neurodevelopmental disorders, eg, cerebral palsy</p>
          </list-item>
          <list-item>
            <p>Individuals who are medical-related technology-dependent (not related to COVID-19), such as tracheostomy, gastrostomy, or PPV (positive pressure ventilation)</p>
          </list-item>
        </list>
        <p>The combination product (bamlanivimab and etesevimab) must be given immediately after a positive test result and within&#x000a0;10 days of symptom onset.&#x000a0;The combination product (etesevimab and bamlanivimab) is not authorized for hospitalized patients with SARS-CoV-2 or those patients requiring oxygen therapy.&#x000a0;</p>
      </sec>
      <sec id="article-132923.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Many glycosylated S proteins layer the surface of SARS-CoV-2,&#x000a0;helping the virus bind to the host cell's ACE2 (Angiotensin-converting enzyme-2 receptor) and facilitating viral entry. The S protein has&#x000a0;2 subunits: S1 and S2. The S1 subunit comprises NTD (N-terminal domain) and RBD (receptor-binding domain).<xref ref-type="bibr" rid="article-132923.r7">[7]</xref>&#x000a0;The&#x000a0;RBD of the S1 subunit binds to the host cell's ACE2. The RBD is a primary target for producing neutralizing monoclonal antibodies.&#x000a0;Etesevimab, bamlanivimab, casirivimab, and imdevimab are neutralizing monoclonal antibodies available against SARS-COV-2. Etesevimab and bamlanivimab bind to the overlapping epitopes in RBD (see <bold>Figures. </bold>Mechanism of Action of Etesevimab, Bamlanivimab, Mechanism of Action of Etesevimab). Casirivimab and imdevimab bind to non-overlapping epitopes of RBD.<xref ref-type="bibr" rid="article-132923.r8">[8]</xref></p>
      </sec>
      <sec id="article-132923.s3" sec-type="Administration">
        <title>Administration</title>
        <p>The authorized dose in adults and pediatric patients (12 years of age and above and weighing 40 kg or more) is 700 mg of bamlanivimab and 1400 mg of etesevimab. The combination product comes in a package with the following.</p>
        <list list-type="order">
          <list-item>
            <p>Bamlanivimab (700 mg) - 1 vial</p>
          </list-item>
          <list-item>
            <p>Etesevimab (700 mg) - 2 vials</p>
          </list-item>
          <list-item>
            <p>Sterile prefilled infusion bag - 0.9% sodium chloride (50 mL, 100 mL, 150 mL, or 250 mL)</p>
          </list-item>
        </list>
        <p>The package should be stored in the refrigerator.&#x000a0;The vials must be warmed to room temperature for 20 minutes before preparation without exposure to direct heat. Withdraw 20 ml and 40 ml of bamlanivimab and etesevimab from vials, then inject them into a prefilled infusion bag. The preparation should not be shaken; gently invert the infusion bag&#x000a0;10 times to mix. The prepared solution can stay at room temperature for 7 hours, including the administration time, and be kept in the refrigerator for 24 hours. If refrigerated, the solution must be warmed to room temperature for 20 minutes before use.<xref ref-type="bibr" rid="article-132923.r9">[9]</xref>&#x000a0;The combination product's compatibility with other medications and IV solutions other than 0.9% sodium chloride is not known. Therefore, it is advisable not to administer the prepared solution with any other medication. After the infusion, flush the tubing with 0.9% sodium chloride to ensure the correct total dose is given.&#x000a0;</p>
      </sec>
      <sec id="article-132923.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The BLAZE-1 trial (randomized, double-blind trial) has witnessed a significant decrease in SARS-CoV-2 viral load among the patients who took bamlanivimab&#x000a0;plus etesevimab compared to the placebo group. The hospitalization and death rates were significantly lower with the antibody group than the placebo group.<xref ref-type="bibr" rid="article-132923.r10">[10]</xref><xref ref-type="bibr" rid="article-132923.r11">[11]</xref></p>
        <list list-type="order">
          <list-item>
            <p>The most frequently reported adverse events were nausea and diarrhea.</p>
          </list-item>
          <list-item>
            <p>Infusion-related reactions can be possible with combination therapy. Signs and symptoms of infusion-related reactions include fever, chills, headache, myalgia, confusion, chest pain, breathing difficulty, wheezing, hypoxia, arrhythmia, hypotension, hypertension, nausea, angioedema, throat irritation, and urticaria. If an infusion-related reaction is suspected, consider slowing or stopping the infusion. Supportive care may be given.</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis or severe hypersensitivity reactions can be possible with bamlanivimab monotherapy or combination therapy. Immediately discontinue the infusion and initiate supportive care.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Clinical worsening of SARS-CoV2 symptoms like fever, hypoxia, and respiratory distress after bamlanivimab monotherapy has been reported. Some of these events required hospitalization.&#x000a0;</p>
          </list-item>
        </list>
        <p>The following adverse events need to be reported within&#x000a0;7 days to the FDA.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Death</p>
          </list-item>
          <list-item>
            <p>A life-threatening adverse event</p>
          </list-item>
          <list-item>
            <p>Inpatient hospitalization&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A significant incapacity&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Medical or surgical intervention to prevent death</p>
          </list-item>
          <list-item>
            <p>A congenital anomaly&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132923.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no strict contraindications to using etesevimab. The following is a list of precautions or warnings while using Etesevimab and Bamlanivimab.</p>
        <list list-type="order">
          <list-item>
            <p><bold>Pregnant patients:&#x000a0; </bold>Etesevimab and bamlanivimab can only be prescribed for pregnant patients with SARS-CoV-2 only if the benefit overbalances the risk for the duo (fetus and mother). Being an IgG antibody, both bamlanivimab and etesevimab can cross the placenta and reach the fetus. However, whether this placental transfer is beneficial or risky for the growing fetus is unclear.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Lactating mother:</bold> No data has shown any potential adverse effects on the breastfed child.<xref ref-type="bibr" rid="article-132923.r12">[12]</xref>&#x000a0;Lactating mothers with SARS-CoV-2 should follow routine practices like wearing masks to avoid exposing the infant to SARS-CoV-2.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Pediatric patients:</bold> Etesevimab and bamlanivimab are not recommended for children less than 12 years or children weighing &#x0003c; 40 Kg.<xref ref-type="bibr" rid="article-132923.r13">[13]</xref> The same adult dose regimen is followed for adolescents weighing &#x0003e;40 kg or &#x0003e;12.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Geriatric patients:</bold>&#x000a0;The pharmacokinetics of etesevimab and bamlanivimab in elderly patients are similar to those of&#x000a0;young adults, so no dose adjustment is required.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Hepatic and Renal Impairment</bold>: The dose adjustment is not required for renal and mild hepatic impairment. However, more studies are required to study the safety of moderate or severe liver impairment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132923.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Etesevimab and bamlanivimab infusions should be given only by a qualified healthcare professional in an outpatient facility who can manage hypersensitive reactions. The patient should be monitored for anaphylaxis for at least&#x000a0;1 hour after infusion completion.</p>
      </sec>
      <sec id="article-132923.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Doses up to 7000 mg of bamlanivimab (10 times the FDA recommended dose) or 7000 mg of etesevimab (5 times the FDA recommended dose ) have been studied in clinical trials, which did not show any of the dose-limiting toxicity. If an overdose of bamlanivimab and etesevimab happens, treatment comprises supportive measures, including vitals and clinical status monitoring. As of now, there is no specific antidote available for the overdose.<xref ref-type="bibr" rid="article-132923.r9">[9]</xref></p>
      </sec>
      <sec id="article-132923.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional healthcare team must communicate with the patient, parent, or caregiver and provide a copy of the fact sheet before administering the combination therapy (bamlanivimab and etesevimab). The fact sheet includes the following information:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The FDA has approved etesevimab and bamlanivimab for emergency use to treat mild to moderate SARS-CoV-2.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>It can be used in adults and pediatrics if they are 12 years old and above, weigh 40 kg or more, and are at high risk of progressing to severe COVID-19 or hospitalization.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The patient or parent/caregiver has the option to accept or refuse.</p>
          </list-item>
          <list-item>
            <p>The potential risks and benefits of medications are unknown.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients treated with bamlanivimab and etesevimab should follow the CDC guidelines (wear a mask, social distancing, avoid sharing personal items, and frequent handwashing).</p>
          </list-item>
        </list>
        <p>Etesevimab and bamlanivimab infusion should be given only by a qualified healthcare professional, and the patient should be monitored for anaphylaxis for at least 1 hour after completing the infusion. The healthcare team comprising the physician, nurse practitioner, and nurse is jointly responsible for reporting medication errors and serious adverse events related to etesevimab and bamlanivimab treatment within&#x000a0;7 days from the onset of the event. The Secretary of the HHS (Department of Health and Human Services) has announced a public health emergency that justifies the EUA of etesevimab and bamlanivimab during the SARS-CoV-2 pandemic. This EUA can be terminated when the HHS secretary finds that the situation justifying the EUA no longer exists. When administering this novel therapy, all interprofessional team members must communicate constantly and operate as a functional unit, collaborating and coordinating their activities and information collection. This includes clinicians, specialists, nurses, and pharmacists operating as a cohesive unit to optimize patient outcomes.</p>
      </sec>
      <sec id="article-132923.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132923&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132923">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/132923/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=132923">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-132923.s10">
        <fig id="article-132923.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Mechanism of Action of&#x000a0;Etesevimab and Bamlanivimab Contributed by P Balasundaram, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Etesevimab__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-132923.s11">
        <fig id="article-132923.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Mechanism of Action of Etesevimab Contributed by P Balasundaram, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Etesevimab__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-132923.s12">
        <title>References</title>
        <ref id="article-132923.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sizikova</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Borisevich</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Shcheblyakov</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Burmistrova</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lebedev</surname>
                <given-names>VN</given-names>
              </name>
            </person-group>
            <article-title>[The use of monoclonal antibodies for the treatment of Ebola virus disease.].</article-title>
            <source>Vopr Virusol</source>
            <year>2018</year>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>245</fpage>
            <page-range>245-249</page-range>
            <pub-id pub-id-type="pmid">30641019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rijal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schimanski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>O'Dowd</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mendelsohn</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cherry</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Labb&#x000e9;</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Donnellan</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Rampling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dowall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rayner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Findlay-Wilson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>XN</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Popplewell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lightwood</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Draper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans.</article-title>
            <source>Cell Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <day>02</day>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>172</fpage>
            <page-range>172-186.e7</page-range>
            <pub-id pub-id-type="pmid">30943399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilina</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Larina</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Aliev</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Dolgikh</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kirpichnikov</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Recombinant Monoclonal Antibodies for Rabies Post-exposure Prophylaxis.</article-title>
            <source>Biochemistry (Mosc)</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">29534663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivapalasingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saviolakis</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kulcsar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hassanein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sumner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elango</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamal</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kyratsous</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Musser</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Frieman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kantrowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weinreich</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lipsich</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus.</article-title>
            <source>J Infect Dis</source>
            <year>2022</year>
            <month>May</month>
            <day>16</day>
            <volume>225</volume>
            <issue>10</issue>
            <fpage>1765</fpage>
            <page-range>1765-1772</page-range>
            <pub-id pub-id-type="pmid">33507266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hurt</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Neutralizing Antibody Therapeutics for COVID-19.</article-title>
            <source>Viruses</source>
            <year>2021</year>
            <month>Apr</month>
            <day>07</day>
            <volume>13</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33916927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ning</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abagna</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Development and application of therapeutic antibodies against COVID-19.</article-title>
            <source>Int J Biol Sci</source>
            <year>2021</year>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1486</fpage>
            <page-range>1486-1496</page-range>
            <pub-id pub-id-type="pmid">33907512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein.</article-title>
            <source>Cell Mol Immunol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>765</fpage>
            <page-range>765-767</page-range>
            <pub-id pub-id-type="pmid">32047258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Focosi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maggi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.</article-title>
            <source>Rev Med Virol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>e2231</fpage>
            <pub-id pub-id-type="pmid">33724631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <article-title>An EUA for bamlanivimab and etesevimab for COVID-19.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2021</year>
            <month>Apr</month>
            <day>05</day>
            <volume>63</volume>
            <issue>1621</issue>
            <fpage>49</fpage>
            <page-range>49-50</page-range>
            <pub-id pub-id-type="pmid">33830966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nirula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Boscia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huhn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mocherla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stosor</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Van Naarden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Custer</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Durante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oakley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schade</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Sabo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Klekotka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Skovronsky</surname>
                <given-names>DM</given-names>
              </name>
              <collab>BLAZE-1 Investigators</collab>
            </person-group>
            <article-title>SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jan</month>
            <day>21</day>
            <volume>384</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-237</page-range>
            <pub-id pub-id-type="pmid">33113295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nirula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boscia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huhn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mocherla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stosor</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Van Naarden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Custer</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Durante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oakley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schade</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Holzer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Higgs</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kallewaard</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Sabo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Klekotka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Skovronsky</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Feb</month>
            <day>16</day>
            <volume>325</volume>
            <issue>7</issue>
            <fpage>632</fpage>
            <page-range>632-644</page-range>
            <pub-id pub-id-type="pmid">33475701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Etesevimab and Bamlanivimab</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">33630482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132923.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abzug</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wattier</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sue</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Zachariah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dulek</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Waghmare</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olivero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Downes</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Pinninti</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Yarbrough</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aldrich</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>MacBrayne</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Soma</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Grapentine</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kimberlin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Bio</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Hankins</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Timberlake</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Orscheln</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Schwenk</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Groves</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Huskins</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Rajapakse</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tribble</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hersh</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Thorell</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Chiotos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2021</year>
            <month>May</month>
            <day>28</day>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>629</fpage>
            <page-range>629-634</page-range>
            <pub-id pub-id-type="pmid">33388760</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
